Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 11 Drug Makers to Increase, 11 to Decrease Hiring Next Year; Mid-Sized Companies Most Optimistic on Hiring
April 15, 2013
- Astellas to Conduct Interim Analysis for PIII Study of Enzalutamide in mCRPC within 2013
April 15, 2013
- Santen to Disclose Payments to Patient Groups in FY2014
April 15, 2013
- Pfizer Japan Launches Intestinal Amebiasis Treatment on April 12
April 12, 2013
- Daiichi Sankyo Sets Up Office of New Company Specialized in DMD Treatments
April 12, 2013
- Daiichi Sankyo Sets Up Office of New Company Specialized in DMD Treatments
April 12, 2013
- Eisai Announces Organizational Reforms; “We Won’t Allow Generics to Overwhelm AD Market”: President Naito
April 12, 2013
- Sanofi K.K. Sales Grew 5.7% in 2012, Plavix Enjoys Sales Success
April 11, 2013
- Ethical Drug Sales Fall 1.7% in February as Flu Season Slows Down: Crecon Report
April 11, 2013
- Teva Pharma Voluntarily Recalls Enalapril Maleate Tablets
April 11, 2013
- Shire Enters Japan Full Force, Six Products to Be Launched in Five Years
April 11, 2013
- Fujimoto’s Safety Procedures TERMS Takes Effect April 1, Celgene’s RevMate June 1
April 10, 2013
- Amgen Plans New Product Debuts in Japan by 2016, Pins Hopes on Hyperlipidemia Drug
April 10, 2013
- Trazenta Now Stands at Starting Line Without Concurrent Use Restrictions: NBI President Aono
April 10, 2013
- DSP to Solely Develop Therapeutic Cancer Vaccines, Terminating Joint Development Agreement with Chugai
April 10, 2013
- Teva Japan: Pres. Shimada to Retire, Eli Lilly’s Kikushige to Take Helm
April 9, 2013
- Kowa, Daiichi Sankyo to End Livalo, Olmetec Marketing Partnership in June
April 9, 2013
- Eisai Sets Up Sales Subsidiary in Russia
April 9, 2013
- Ajinomoto Acquires US-Based Althea Technologies to Expand Biotech Operations
April 9, 2013
- Rubella Epidemic Triggers Vaccine Shipment Adjustments at Drug Makers
April 9, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…